



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/66, 9/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/29679</b> <b>(43) International Publication Date:</b> 9 November 1995 (09.11.95)
<b>(21) International Application Number:</b> PCT/US95/04965 <b>(22) International Filing Date:</b> 24 April 1995 (24.04.95) <b>(30) Priority Data:</b> 236,904                      29 April 1994 (29.04.94)                      US  <b>(60) Parent Application or Grant</b> (63) Related by Continuation US    236,904 (CON) Filed on                                      29 April 1994 (29.04.94)  <b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KATDARE, Ashok, V. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). KRAMER, Kenneth, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).  <b>(74) Common Representative:</b> MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		<b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> WET GRANULATION FORMULATION FOR BISPHOSPHONIC ACIDS  <b>(57) Abstract</b>  Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AT</b>	Austria	<b>GB</b>	United Kingdom	<b>MR</b>	Mauritania
<b>AU</b>	Australia	<b>GE</b>	Georgia	<b>MW</b>	Malawi
<b>BB</b>	Barbados	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BE</b>	Belgium	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BF</b>	Burkina Faso	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BG</b>	Bulgaria	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BJ</b>	Benin	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BR</b>	Brazil	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BY</b>	Belarus	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>CA</b>	Canada	<b>KG</b>	Kyrgyzstan	<b>RU</b>	Russian Federation
<b>CF</b>	Central African Republic	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CG</b>	Congo	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CH</b>	Switzerland	<b>KZ</b>	Kazakhstan	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LI</b>	Liechtenstein	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LK</b>	Sri Lanka	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LV</b>	Latvia	<b>TD</b>	Chad
<b>CS</b>	Czechoslovakia	<b>LU</b>	Luxembourg	<b>TG</b>	Togo
<b>CZ</b>	Czech Republic	<b>LY</b>	Libya	<b>TJ</b>	Tajikistan
<b>DE</b>	Germany	<b>MC</b>	Monaco	<b>TT</b>	Trinidad and Tobago
<b>DK</b>	Denmark	<b>MD</b>	Republic of Moldova	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>MG</b>	Madagascar	<b>US</b>	United States of America
<b>FI</b>	Finland	<b>ML</b>	Mali	<b>UZ</b>	Uzbekistan
<b>FR</b>	France	<b>MN</b>	Mongolia	<b>VN</b>	Viet Nam
<b>GA</b>	Gabon				

- 1 -

TITLE OF THE INVENTIONWET GRANULATION FORMULATION FOR BISPHOSPHONIC  
ACIDS5 BACKGROUND OF THE INVENTION

The pharmaceutical industry employs various methods for compounding pharmaceutical agents in tablet formulations. In particular, wet granulation is one of the most prevalent methods. Tablets prepared by wet granulation generally require the addition of a  
10 binding agent to keep the tablet together.

A variety of bisphosphonic acids have been disclosed as being useful in the treatment and prevention of diseases involving bone resorption. Representative examples may be found in the following:  
15 U.S. Patent No. 3,962,432; U.S. Patent No. 4,054,598;  
U.S. Patent No. 4,267,108; U.S. Patent No. 4,327,039;  
U.S. Patent No. 4,621,077; U.S. Patent No. 4,624,947;  
U.S. Patent No. 4,746,654; U.S. Patent No. 4,922,077; and EPO Patent  
Pub. No. 0,252,504. Standard methods for tablet formulation of  
20 bisphosphonic acids, however, suffer difficulties.

Wet granulated formulations need to have an agent called a "binder," which, in contact with water, swells or starts dissolving, forming a gel-like consistency. Traditionally, starch, starch paste, gelatin, and cellulose derivatives such as hydroxypropylmethyl cellulose,  
25 hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone are used as binding agents in wet granulation formulations. (See, Remington's Pharmaceutical Sciences, 18th ed, (Mack Publishing Company: Easton, PA, 1990), pp.1635-36). Microcrystalline cellulose, such as Avicel PH101, may be employed as a binder or compression aid in compositions prepared by dry granulation formulation, but  
30 microcrystalline cellulose functions primarily as a bulking agent in wet granulation formulations because the microcrystalline cellulose loses much of its binding properties upon wetting.

The wet granulation process helps to form agglomerates of powders. These agglomerates are called "granules." The present

- 2 -

invention provides for a wet granulated formulation of bisphosphonic acids and process therefor wherein the tablet formulation does not contain any binder. Instead, the drug itself acts as a binder. The absence of a separate binder keeps the formulation simpler, and  
5 minimizes adverse effects that binding agents can have on dissolution. Elimination of binder also simplifies the optimization and characterization of the formulation.

### 10 DESCRIPTION OF THE INVENTION

The present invention is directed in a first embodiment to a process for the preparation of pharmaceutical compositions of bisphosphonic acids by wet granulation formulation. This process employs a blend of a bisphosphonic acid and minimal amounts of other processing aids with no binder added. This tablet formulation is  
15 prepared by:

- (1) forming a powder blend of the active ingredient with diluents,
- (2) wet granulating the powder blend with water to form  
20 granules,
- (3) drying the granules to remove water, and
- (4) compressing the lubricated granule mixture into a desired tablet form.

The shape of the tablet is not critical.

More specifically, this embodiment of the present invention  
25 concerns a process for the preparation of a tablet containing a bisphosphonic acid as an active ingredient which process comprises:

- (1) forming a powder blend of the active ingredient with diluents from 3 to 25 minutes using a mixer such as a planetary or high shear granulator,
- 30 (2) wet granulating the powder blend by the addition of water while mixing over a 2 to 30 minute period to form granules,

- 3 -

- 5
- (3) drying the granules to remove water by the use of heated air for 10 minutes to 24 hours in a dryer (fluid bed or tray type),
- (4) milling the dried granules to a uniform size,
- (5) adding and blending a disintegrant with the dried milled particles for 2 to 30 minutes,
- (6) adding and blending a lubricant to the mixture containing the disintegrant for 30 seconds to 20 minutes, and
- 10 (7) compressing the lubricated granule mixture into a desired tablet form.

15 One particularly preferred process employs a high shear granulator as a mixer and comprises the steps of:

- (1) forming a powder blend of 4-amino-1-hydroxy-butyridene-1,1-bisphosphonic acid, microcrystalline cellulose, such as Avicel PH101, and lactose with a high shear granulator for 3 to 5 minutes ,
- 20 (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 5 minute period to form granules with the high shear granulator,
- (3) drying the granules to remove water by the use of heated air by drying 10 minutes to 1 hour with a fluid bed, or 12-24 hours in a tray dryer, preferably with a fluid bed,
- 25 (4) milling the dried granules to a uniform size using a hammer type mill,
- (5) adding and blending the disintegrant croscarmellose sodium NF type A with the dried milled particles for 3 to 8 minutes,
- 30 (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender or a planetary mixer for 3 to 8 minutes, and

- 4 -

- (7) compressing the lubricated granule mixture into a desired tablet form, and
- (8) dedusting and storing the tablets.

5

Another particularly preferred process employs a planetary granulator as a mixer and comprises the steps of:

10

15

20

25

30

- (1) forming a powder blend of 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, microcrystalline cellulose such as Avicel PH101, and lactose with a planetary granulator for 10 to 25 minutes ,
- (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 10 minute period to form granules with the planetary granulator,
- (3) drying the granules to remove water by the use of heated air by drying 10 minutes to 1 hour with a fluid bed, or 12-24 hours in a tray dryer, preferably with a fluid bed,
- (4) milling the dried granules to a uniform size using a hammer type mill,
- (5) adding and blending the disintegrant croscarmellose sodium NF type A with the dried milled particles for 3 to 8 minutes,
- (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender or a planetary granulator for 3 to 8 minutes, and
- (7) compressing the lubricated granule mixture into a desired tablet form, and
- (8) dedusting and storing the tablets.

Still another particularly preferred process employs a high shear granulator as mixer, and comprises the steps of:

- 5 -

- (1) forming a powder blend of 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, microcrystalline cellulose, such as Avicel PH101, and lactose with a high shear granulator for 3 to 5 minutes,
- (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 5 minute period to form granules with a high shear granulator,
- (3) drying the granules to remove water by the use of heated air for 10 minutes to one hour using a fluid bed dryer,
- (4) milling the dried granules to a uniform size using a hammer type mill,
- (5) adding and blending the disintegrant croscarmellose sodium NF type A with the dried milled particles for 3 to 8 minutes,
- (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender for 3 to 8 minutes,
- (7) compressing the lubricated granule mixture into a desired tablet form, and
- (8) dedusting and storing the tablets.

Granulation is the process of adding water to a powder mixture with mixing until granules are formed. The granulation step may be varied from 2 to 30 minutes, preferably 2 to 5 minutes. The lubrication step is the process of adding lubricant to the mixture; the lubrication step may be varied from 30 seconds to 20 minutes, preferably 3 to 8 minutes.

The disclosed process may be used to prepare solid dosage forms, particularly tablets, for medicinal administration.

Preferred diluents include: lactose, microcrystalline cellulose, calcium phosphate(s), mannitol, powdered cellulose, pregelatinized starch, and other suitable diluents. Especially preferred

- 6 -

are lactose and microcrystalline cellulose. In particular, microcrystalline cellulose NF, especially Avicel PH101, the trademarked name for microcrystalline cellulose NF manufactured by FMC Corp. is preferred.

5 The disintegrant may be one of several modified starches or modified cellulose polymers, in particular, croscarmellose sodium is preferred. Croscarmellose sodium NF Type A is commercially available under the trade name "Ac-di-sol".

10 Preferred lubricants include magnesium stearate, calcium stearate, stearic acid, surface active agents such as sodium lauryl sulfate, propylene glycol, sodium dodecane sulfonate, sodium oleate sulfonate, and sodium laurate mixed with stearates and talc, sodium stearyl fumarate, and other known lubricants. Especially preferred is magnesium stearate.

15 Examples of the bisphosphonic acids which may be employed as active ingredients in the instant invention include:

- (a) 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
- 20 (b) N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
- (c) 4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid;
- (d) 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;
- 25 (e) 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;
- (f) 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;
- 30 (g) 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid; and
- (h) 4-(hydroxymethylene-1,1-bisphosphonic acid)-piperidine;

or pharmaceutically acceptable salts thereof.



- 7 -

Methods for the preparation of bisphosphonic acids may be found in, e.g., U.S. Patent No. 3,962,432; U.S. Patent No. 4,054,598; U.S. Patent No. 4,267,108; U.S. Patent No. 4,327,039; U.S. Patent No. 4,407,761; U.S. Patent No. 4,621,077; U.S. Patent No. 4,624,947; U.S. Patent No. 4,746,654; U.S. Patent No. 4,922,077; and EPO Patent Pub. No. 0,252,504. In particular, methods for the preparation of 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid and 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid monosodium salt trihydrate may be found in U.S. Patent No. 4,407,761 and U.S. Patent No. 4,922,077, respectively.

The pharmaceutically acceptable salts of bisphosphonic acids may also be employed in the instant invention. Examples of base salts of bisphosphonic acids include ammonium salts, alkali metal salts such as potassium and sodium (including mono-, di- and tri-sodium) salts (which are preferred), alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. The non-toxic, physiologically acceptable salts are preferred. The salts may be prepared by methods known in the art, such as in U.S. Patent No. 4,922,077.

In the present invention it is preferred that the bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid. It is even more preferred that the bisphosphonic acid is a sodium salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, in particular, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.

Preferred pharmaceutical compositions comprise about 0.5 to 40% by weight of a bisphosphonic acid as an active ingredient; about 10 to 80% by weight of anhydrous lactose or hydrous fast flow lactose; about 5 to 50% by weight of microcrystalline cellulose; and about 0.1 to 5% by weight of magnesium stearate.

The preferred pharmaceutical compositions are generally in the form of tablets. The tablets may be, for example, from 50 mg to

- 8 -

1.0 g in net weight, more preferably 100 to 500 mg net weight, and even more preferably 150 to 300 mg net weight.

More preferred pharmaceutical compositions in accordance with the present invention comprise: about 0.5 to 25% by weight of a  
5 bisphosphonic acid selected from 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid and 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate; about 30 to 70% by weight of anhydrous lactose or hydrous fast flow lactose; about 30 to 50% by  
10 weight of microcrystalline cellulose; about 0.1 to 2% by weight of magnesium stearate; and about 0.5 to 2% by weight of a disintegrant such as croscarmellose sodium.

Especially preferred pharmaceutical compositions comprise about 1 to 25% of the active ingredient, about 40 to 60% by weight of  
15 anhydrous lactose; about 35 to 45% by weight of microcrystalline cellulose; about 0.5 to 2% by weight of croscarmellose sodium; and about 0.1 to 1% by weight of magnesium stearate. Preferred pharmaceutical compositions as envisioned for commercial development are as follows.

Tablets of 2.5 mg potency free acid:  
20 about 1.63% by weight of 4-amino-1-hydroxy- butylidene-1,1-bisphosphonic acid monosodium salt trihydrate; about 56.87% by weight of anhydrous lactose; about 40% by weight of microcrystalline cellulose; about 1% by weight of croscarmellose sodium; and about  
25 0.5% by weight of magnesium stearate.

Tablets of 5 mg potency free acid:  
about 3.25% by weight of 4-amino-1-hydroxy- butylidene-1,1-bisphosphonic acid monosodium salt trihydrate; about 55.25% by  
weight of anhydrous lactose; about 40% by weight of microcrystalline  
30 cellulose; about 1% by weight of croscarmellose sodium; and about 0.5% by weight of magnesium stearate.

Tablets of 10 mg potency free acid:  
about 6.5% by weight of 4-amino-1-hydroxy- butylidene-1,1-bisphosphonic acid monosodium salt trihydrate; about 52.0% by  
weight of anhydrous lactose; about 40% by weight of microcrystalline

- 9 -

cellulose; about 1% by weight of croscarmellose sodium; and about 0.5% by weight of magnesium stearate.

Tablets of 20 mg potency free acid:

5       about 13.0% by weight of 4-amino-1-hydroxy- butylidene-  
1,1-bisphosphonic acid monosodium salt trihydrate; about 45.5% by  
weight of anhydrous lactose; about 40% by weight of microcrystalline  
cellulose; about 1% by weight of croscarmellose sodium; and about  
0.5% by weight of magnesium stearate.

Tablets of 40 mg potency free acid:

10       about 26.0% by weight of 4-amino-1-hydroxy-butylidene-  
1,1-bisphosphonic acid monosodium salt trihydrate; about 32.5% by  
weight of anhydrous lactose; about 40% by weight of microcrystalline  
cellulose; about 1% by weight of croscarmellose sodium; and about  
0.5% by weight of magnesium stearate.

15       Each of the tablets of the potencies above is preferably  
formulated in a 200 mg tablet containing 0.05 mL purified water USP  
per tablet.

20       The pharmaceutical tablet compositions of the present  
invention may also contain one or more additional formulation  
ingredients may be selected from a wide variety of excipients known in  
the pharmaceutical formulation art. According to the desired properties  
of the tablet, any number of ingredients may be selected, alone or in  
combination, based upon their known uses in preparing tablet  
compositions. Such ingredients include, but are not limited to, diluents,  
25       compression aids, disintegrants, lubricants, flavors, flavor enhancers,  
sweetener and preservatives. The pharmaceutical tablet compositions of  
the present invention do not, however, require the addition of a separate  
binding excipient because in wet granulation the active ingredient itself  
acts as a binding agent.

30       The term "tablet" as used herein is intended to encompass  
compressed pharmaceutical dosage formulations of all shapes and sizes,  
whether coated or uncoated. Substances which may be used for coating  
include hydroxypropylmethylcellulose, hydroxypropylcellulose,  
titanium dioxide, talc, sweeteners, and colorants.

- 10 -

The pharmaceutical compositions of the present invention are useful in the therapeutic or prophylactic treatment of disorders in calcium or phosphate metabolism and associated diseases. These diseases can be divided into two categories:

5

1. Abnormal (ectopic) depositions of calcium salts, mostly calcium phosphate, pathological hardening of tissues and bone malformations.

10

2. Conditions which can benefit from a reduction in bone resorption. A reduction in bone resorption should improve the balance between resorption and formation, reduce bone loss or result in bone augmentation. A reduction in bone resorption can alleviate the pain associated with osteolytic lesions and reduce the incidence and/or growth of those lesions.

15

These diseases include: osteoporosis (including estrogen deficiency, immobilization, glucocorticoid induced and senile), osteodystrophy, Paget's disease, myositis ossificans, Bechterew's disease, malignant hypercalcemia, metastatic bone disease, periodontal disease, cholelithiasis, nephrolithiasis, urolithiasis, urinary calculus, hardening of the arteries (sclerosis), arthritis, bursitis, neuritis and tetany.

20

Increased bone resorption can be accompanied by pathologically high calcium and phosphate concentrations in the plasma, which would be alleviated by use of the instant pharmaceutical compositions.

25

The following examples are given for the purpose of illustrating the present invention and shall not be construed as being limitations on the scope or spirit of the invention.

30

- 11 -

EXAMPLE 1

Procedure for Manufacturing 2.5 mg Potency Tablets of 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid

5

Ingredients	Per Tablet	Per 10,000 Tablets
Active ingredient (monosodium salt trihydrate)	3.26 mg	32.6 g
Anhydrous Lactose, NF	113.74 mg	1137.4 g
Microcrystalline Cellulose NF	80.0 mg	800.0 g
Magnesium Stearate Impalpable Powder NF	1.00 mg	10.0 g
Croscarmellose Sodium NF Type A	2.00 mg	20.0 g

10

15

20

25

30

The active ingredient (equivalent to 2.5 mg anhydrous free acid per tablet) was mixed with the microcrystalline cellulose NF and the anhydrous lactose NF in a high shear mixer for 3 minutes. Granulating solvent (550 mL water) was added to this blend with the mixer running over a two minute period. The wetted mass was dried in a fluid bed dryer at an inlet temperature of 50°C. The dried material was then milled using a FITZPATRICK J mill (hammer-type mill) to achieve fine granules. After milling, Croscarmellose Sodium NF type A (disintegrant) was added to the blend and mixed in a ribbon blender for 5 minutes. Magnesium Stearate Impalpable Powder NF (lubricant) was added to this blend through a #60 mesh screen and blended for an additional 4 minutes. The lubricated mixture was compressed to provide tablets of 2.5 mg active ingredient.

- 12 -

EXAMPLE 2

Procedure for Manufacturing 10 mg Potency Tablets of 4-Amino-1-  
hydroxybutylidene-1,1-bisphosphonic acid

5

<u>Ingredients</u>		<u>Per Tablet</u>	<u>Per 10,000 Tablets</u>
10	Active ingredient (monosodium salt trihydrate)	13.05 mg	130.5 g
	Anhydrous Lactose, NF	103.95 mg	1039.5 g
15	Microcrystalline Cellulose NF	80.0 mg	800.0 g
	Magnesium Stearate Impalpable Powder NF	1.00 mg	10.0 g
20	Croscarmellose Sodium NF Type A	2.00 mg	20.0 g

Tablets were prepared using essentially the procedure of  
Example 1.

25

30

- 13 -

EXAMPLE 3

Procedure for Manufacturing 20 mg Potency Tablets of 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid

5

5	<u>Ingredients</u>	<u>Per Tablet</u>	<u>Per 10,000 Tablets</u>
10	Active ingredient (monosodium salt trihydrate)	26.11 mg	261.1 g
15	Anhydrous Lactose, NF	90.89 mg	908.9 g
15	Microcrystalline Cellulose NF	80.0 mg	800.0 g
20	Magnesium Stearate Impalpable Powder NF	1.0 mg	10.0 g
20	Croscarmellose Sodium NF Type A	2.0 mg	20.0 g

Tablets were prepared using essentially the procedure of Example 1.

25

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the casual variations, adaptations, modifications, deletions, or additions of procedures and protocols described herein, as

30

come within the scope of the following claims and its equivalents.

- 14 -

WHAT IS CLAIMED IS:

1. A process for the preparation of a tablet containing  
an active ingredient selected from the group consisting of:
- 5 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
N-methyl-4-amino-1-hydroxybutylidene-1,1-  
bisphosphonic acid;  
4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-  
bisphosphonic acid;
- 10 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;  
3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-  
bisphosphonic acid;  
1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-  
bisphosphonic acid;
- 15 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid;  
and  
4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine;  
or a pharmaceutically acceptable salt thereof;
- 20 which process comprises:
- (1) forming a powder blend of the active ingredient with  
diluent,
- (2) wet granulating the powder blend with water to form  
granules,
- 25 (3) drying the granules to remove water, and  
(4) compressing the dried granules mixture into a desired  
tablet form.
2. The process of Claim 1 wherein the active ingredient  
30 is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid.
3. The process of Claim 1 wherein the active ingredient  
is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium  
salt trihydrate.



- 15 -

4. A process for the preparation of a tablet containing an active ingredient selected from the group consisting of:

- 5 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
N-methyl-4-amino-1-hydroxybutylidene-1,1-  
bisphosphonic acid;  
4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-  
bisphosphonic acid;  
3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;  
10 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-  
bisphosphonic acid;  
1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-  
bisphosphonic acid;  
1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid;  
and  
15 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine;  
or a pharmaceutically acceptable salt thereof;

which process comprises:

- 20 (1) forming a powder blend of the active ingredient with  
diluent from 3 to 25 minutes using a mixer such as a  
planetary or high shear granulator,  
(2) wet granulating the powder blend by the addition of water  
while mixing over a 2 to 30 minute period to form  
granules,  
25 (3) drying the granules to remove water by the use of heated  
air for 10 minutes to 24 hours,  
(4) milling the dried granules to a uniform size,  
(5) adding and blending a disintegrant with the dried milled  
particles for 2 to 30 minutes,  
30 (6) adding and blending a lubricant to the mixture containing  
the disintegrant for 30 seconds to 20 minutes, and  
(7) compressing the dried granules mixture into a desired  
tablet form.

- 16 -

5. The process of Claim 4 wherein the active ingredient is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid.
- 5 6. The process of Claim 4 wherein the active ingredient is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- 10 7. The process of Claim 4 wherein the diluents are selected from: lactose, microcrystalline cellulose, calcium phosphate, mannitol, powdered cellulose, and pregelatinized starch.
8. The process of Claim 7 wherein the diluents are lactose and microcrystalline cellulose.
- 15 9. The process of Claim 8 wherein the lactose is lactose NF anhydrous and the microcrystalline cellulose is Avicel PH101.
- 20 10. The process of Claim 4 wherein the disintegrant is selected from the group consisting of modified starch, modified cellulose polymer, and croscarmellose sodium, or a combination thereof.
- 25 11. The process of Claim 10 wherein the disintegrant is croscarmellose sodium.
12. The process of Claim 11 wherein the disintegrant is croscarmellose sodium NF type A.
- 30 13. The process of Claim 4 wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, sodium lauryl sulfate, propylene glycol, sodium dodecane sulfonate, sodium oleate sulfonate, sodium laurate mixed with stearates and talc, and sodium stearyl fumarate.

- 17 -

14. The process of Claim 13 wherein the lubricant is magnesium stearate.

- 5           15. The process of Claim 4 which comprises the steps:
- (1) forming a powder blend of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, microcrystalline cellulose, and lactose with a high shear granulator for 3 to 5 minutes ,
  - 10           (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 5 minute period to form granules with the high shear granulator,
  - 15           (3) drying the granules to remove water by the use of heated air by drying 10 minutes to 1 hour with a Fluid bed, or 12 to 24 hours in a tray dryer,
  - 20           (4) milling the dried granules to a uniform size using a hammer type mill,
  - (5) adding and blending the disintegrant croscarmellose sodium NF type A with the dried milled particles for 3 to 8 minutes,
  - 25           (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender or a planetary mixer for 3 to 8 minutes,
  - (7) compressing the lubricated granule mixture into a desired tablet form, and
  - 30           (8) dedusting and storing the tablets.

16. The process of Claim 4 which comprises the steps:
- (1) forming a powder blend of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid,

- 18 -

- microcrystalline cellulose, and lactose with a planetary granulator for 10 to 25 minutes ,
- 5 (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 10 minute period to form granules with the planetary granulator,
- (3) drying the granules to remove water by the use of heated air by drying 10 minutes to 1 hour with a fluid bed, or 12-24 hours in a tray
- 10 dryer,
- (4) milling the dried granules to a uniform size using a hammer type mill,
- (5) adding and blending the disintegrant croscarmellose sodium NF type A with the
- 15 dried milled particles for 3 to 8 minutes,
- (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender or a planetary
- 20 granulator for 3 to 8 minutes, and
- (7) compressing the lubricated granule mixture into a desired tablet form, and
- (8) dedusting and storing the tablets.
- 25 17. The process of Claim 4 which comprises the steps:
- (1) forming a powder blend of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, Avicel PH101 microcrystalline cellulose, and
- 30 lactose with a high shear granulator for 3 to 5 minutes,
- (2) wet granulating the powder blend by the addition of water while mixing over a 3 to 5 minute period to form granules with a high shear granulator,

- 19 -

- 5
- (3) drying the granules to remove water by the use of heated air for 10 minutes to one hour using a fluid bed dryer,
- (4) milling the dried granules to a uniform size using a hammer type mill,
- (5) adding and blending the disintegrant croscarmellose sodium NF type A with the dried milled particles for 3 to 8 minutes,
- 10 (6) adding and blending magnesium stearate lubricant to the mixture containing the croscarmellose sodium NF type A disintegrant with a ribbon blender for 3 to 8 minutes,
- (7) compressing the lubricated granule mixture into a desired tablet form, and
- 15 (8) dedusting and storing the tablets.

18. A solid dosage form containing an active ingredient selected from the group consisting of:

- 20 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
- N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
- 4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid;
- 25 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;
- 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;
- 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;
- 30 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid;
- and
- 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine;
- or a pharmaceutically acceptable salt thereof;

wherein the dosage form is prepared by the process of Claim 1.

- 20 -

19. A pharmaceutical composition comprising by weight, about 0.5 to 25% by weight of an active ingredient selected from the group consisting of:

- 5 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid;  
10 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;  
3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;  
1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;  
15 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid;  
and  
4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine;  
or a pharmaceutically acceptable salt thereof;

20 and from about 30 to 70 % by weight of anhydrous lactose or hyrous fast flow lactose; about 30 to 50 % by weight of microcrystalline cellulose, and about 0.1 to 2% by weight magnesium stearate.

20. The pharmaceutical composition of Claim 19 comprising about 1 to 25% by weight of the active ingredient, about 40 to 60% by weight of anhydrous lactose; about 35 to 45% by weight of microcrystalline cellulose; about 0.5 to 2% by weight croscarmellose sodium and about 0.1 to 1% by weight of magnesium stearate.

21. The pharmaceutical composition of Claim 18 wherein the active ingredient is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid.

- 21 -

22. The pharmaceutical composition of Claim 18 wherein the active ingredient is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.

5                   23. The pharmaceutical composition of Claim 20 wherein the active ingredient is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.

10                   24. A tablet prepared from the pharmaceutical composition of Claim 23.

                  25. A tablet prepared from the pharmaceutical composition of Claim 18.

15

20

25

30

## INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 95/04965

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K31/66 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 566 535 (CIBA-GEIGY AG) 20 October 1993 see page 7; example 3 ---	18
X	EP,A,0 421 921 (CIBA-GEIGY) 10 April 1991 see page 3, line 2 - line 17 see page 5, line 22 - line 27 ---	18
X	EP,A,0 336 851 (SANOFI S.A.) 11 October 1989 see page 3 - page 4; example 1 ---	18
X	FR,A,2 259 615 (HENKEL & CIE GMBH) 29 August 1975 see page 6 - page 7; example 4 ---	18
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 August 1995

Date of mailing of the international search report

05.09.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+ 31-70) 340-3016

Authorized officer

Boulois, D



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/04965

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP,A,0 623 347 (ELF SANOFI) 9 November 1994 see claim 6 ----	18
P,X	WO,A,94 12200 (MERCK & CO INC) 9 June 1994 see page 8; example 1 ----	18-25
A	WO,A,93 21907 (LEIRAS OY) 11 November 1993 see page 4 - page 5; example 1 ----	1-17
A	EP,A,0 282 320 (YAMANOUCHI PHARM. CO LTD) 14 September 1988 see page 48, line 50 - page 49, line 1 ----	1-17
X	EP,A,0 177 443 (CIBA-GEIGY) 9 April 1986 see page 24; example 2 ----	18
A	WO,A,92 11269 (HUHTAMÄKI OY) 9 July 1992 see page 21, line 5 - line 15 -----	1-17

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No  
PCT/US 95/04965

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-566535	20-10-93	AU-B-	3696193	21-10-93
		JP-A-	6009408	18-01-94
		NZ-A-	247398	26-07-95
		US-A-	5344825	06-09-94
		ZA-A-	9302613	26-10-93
-----				
EP-A-421921	10-04-91	AU-B-	623036	30-04-92
		AU-A-	6228390	14-03-91
		CA-A-	2024631	08-03-91
		DE-D-	59005517	01-06-94
		ES-T-	2052228	01-07-94
		FI-B-	93169	30-11-94
		JP-A-	3099016	24-04-91
		NO-B-	176646	30-01-95
		US-A-	5096717	17-03-92
-----				
EP-A-336851	11-10-89	FR-A-	2629716	13-10-89
		AU-A-	3258889	12-10-89
		CA-A-	1327009	15-02-94
		IE-B-	60923	07-09-94
		JP-A-	2006409	10-01-90
		OA-A-	9415	15-10-92
		SG-A-	17193	21-01-94
		US-A-	4980171	25-12-90
-----				
FR-A-2259615	29-08-75	DE-A-	2405254	14-08-75
		AT-B-	332557	11-10-76
		BE-A-	822930	04-06-75
		CA-A-	1033666	27-06-78
		CH-A-	610201	12-04-79
		GB-A-	1435885	19-05-76
		JP-A-	50107148	23-08-75
		NL-A-	7414947	06-08-75
US-A-	3962432	08-06-76		
-----				
EP-A-623347	09-11-94	FR-A-	2703590	14-10-94
		AU-B-	5910294	06-10-94
		CA-A-	2120538	06-10-94
		HU-A-	68310	28-06-95
		JP-A-	7048261	21-02-95

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/04965

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-623347		NO-A- 941185	06-10-94
WO-A-9412200	09-06-94	US-A- 5358941	25-10-94
		AU-B- 5611594	22-06-94
		CN-A- 1098907	22-02-95
		FI-A- 952685	01-06-95
		NO-A- 952184	01-06-95
WO-A-9321907	11-11-93	SE-C- 501389	30-01-95
		AU-B- 3955093	29-11-93
		CZ-A- 9402614	15-02-95
		DE-T- 637236	06-07-95
		EP-A- 0637236	08-02-95
		FI-A- 944961	21-10-94
		JP-T- 7505898	29-06-95
		NO-A- 944001	21-10-94
		SE-A- 9201299	25-10-93
EP-A-282320	14-09-88	AU-B- 607194	28-02-91
		AU-A- 1289788	08-09-88
		DE-A- 3866737	23-01-92
		JP-A- 2000185	05-01-90
		US-A- 4973576	27-11-90
EP-A-177443	09-04-86	AU-B- 591066	30-11-89
		AU-A- 4577785	13-02-86
		CA-A- 1255694	13-06-89
		IE-B- 58077	30-06-93
		JP-C- 1797264	28-10-93
		JP-B- 5008717	02-02-93
		JP-A- 61043196	01-03-86
		KR-B- 9400817	02-02-94
		US-A- 4639338	27-01-87
		US-A- 4711880	08-12-87
WO-A-9211269	09-07-92	FI-B- 89366	15-06-93
		AU-A- 9068291	22-07-92
		CN-A- 1062534	08-07-92
		CZ-A- 9301217	19-10-94
		EP-A- 0563107	06-10-93

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/04965

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9211269		HU-A- 64549	28-01-94
		JP-T- 6504769	02-06-94
		NZ-A- 241040	26-07-94
		US-A- 5393748	28-02-95
-----			